logo
Plus   Neg
Share
Email

Agilent Gets FDA Approval For PD-L1 Companion Diagnostic On Dako Omnis

Agilent Technologies Inc. (A) said that the U.S. Food and Drug Administration has
approved the company's PD-L1 IHC 22C3 pharmDx as a companion diagnostic or CDx
to identify patients with non-small cell lung cancer who are appropriate for
first-line monotherapy with KEYTRUDA or pembrolizumab on the Dako Omnis platform.

Dako Omnis is Agilent's fully automated, walk-away solution for staining
tumor samples that provides a flexible, high-throughput diagnostic service
integrated into the core of the laboratory workflow.

Lung cancer is the leading cause of cancer-related mortality in the United
States, with an estimated incidence of 142,000 deaths in 2019 alone.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Securities and Exchange Commission is investigating the circumstances around Eastman Kodak Co.'s (KODK) announcement of a $765 million government loan to make ingredients for Covid-19 drugs, the Wall Street Journal reported citing people familiar with the matter. The National Retail Federation or NRF said that conflicting economic data amid a resurgence in coronavirus cases has made it difficult to predict how steadily the U.S. economic recovery will continue. NRF Chief Economist Jack Kleinhenz noted that based on quarterly and monthly data, the U.S. economic recovery is continuing despite the elevated COVID-19 cases. Ford Motor Company (F) announced that Jim Hackett plans to retire as President and CEO. He will continue as a special advisor to the company through March of 2021. The company has named Jim Farley as new president and CEO. He will join the board of directors, effective Oct. 1. Farley joined Ford in...
Follow RTT